Gmail Calendar Documents Reader Web more »
Help | Sign in
Go to Google Groups Home
   
Discussions for United Therapeutics Corporation View all discussions
My starred discussions
My profile

  UTHR - Hold
Only 1 message in discussion  - 
Reporting discussion
Messages reported
The group you are posting to is a Usenet group. Messages posted to this group will make your email address visible to anyone on the Internet.
Your reply message has not been sent.
Your post was successful
 
From:
To:
Cc:
Followup To:
Add Cc | Add Followup-to | Edit Subject
Subject:
Validation:
For verification purposes please type the characters you see in the picture below or the numbers you hear by clicking the accessibility icon. Listen and type the numbers you hear
 
profit...@gmail.com  
View profile  
 More options Mar 21 2006, 8:52 pm
From: Profit...@gmail.com
Date: Tue, 21 Mar 2006 17:52:55 -0800
Local: Tues, Mar 21 2006 8:52 pm
Subject: UTHR - Hold
Forward | Print | Individual message | Report this message | Find messages by this author
It is priced to perfection in the PAH space.  They missed the
enrollment figures for the inhaled version of Remodulin and hence have
been put behind.  However, if their inhaled version does take off, it
will be the end for the major competitors: Actelion, ENCY, MYOG,
Vevantis, Pfizer, etc. Of better future prospects are the cancer
fighting drugs: OvaRex, BrevaRex, PostaRex, etc.

I will be watching this one carefully.  It has the potential to become
another Amgen, Genentech if they execute well.


    Forward  
You must Sign in before you can post messages.
To post a message you must first join this group.
Please update your nickname on the subscription settings page before posting.
You do not have the permission required to post.

End of messages  

« Newer discussion  -  How much of this medicine are they going to sell anyway?   No older discussions




Google Home - Terms of Service - Privacy Policy

©2010 Google